Lyrica pregabalin regulatory update

Pfizer said it received approval in Japan for an expanded label for Lyrica pregabalin that replaces the previous indication of peripheral neuropathic pain with a broader indication of neuropathic pain. Lyrica was first approved in Japan in June 2010 for postherpetic neuralgia. In October 2010, the product was approved for broader indication of peripheral neuropathic pain, which includes postherpetic neuralgia (PHN). The GABA receptor agonist is also approved in Japan to treat pain associated with fibromyalgia. Pfizer co-promotes Lyrica in Japan with Eisai Co. Ltd. (Tokyo:4523; Osaka:4523, Tokyo, Japan). ...